P46375 8th Annual Cell Line Development and Engineering Asia
Download Brochure Request

Register your interest

Comments

Register your interest

Comments

8th Annual Cell Line Development and Engineering Asia

14 – 16 May 2019, Shanghai Marriott Hotel Parkview, China.

Book Now Download Brochure

LOCAL CHINA COMPANIES RATES AVAILABLE. 中国企业可享有独家优惠价!
SPECIAL GROUP RATES FOR 2 OR MORE. 2名及以上代表注册立享团队优惠价。SEE PRICING BELOW.

overview

The global market size for cell line development is expected to exceed USD 7.5 billion by 2024. Some key market drivers include the demand for cell therapies, growing oncology market, increasing demand for vaccines and monoclonal antibodies, and continued growth in the vaccine market.

Aimed at providing a commercial snapshot of new market opportunities, yet retaining its focus on scientific and technical best practice use cases, the 8th Annual Cell Line Development & Engineering Asia summit will continue to provide unique learning and sharing opportunities for the industry.

Discussion themes

  • Impact of the surging biologics and cell therapy market on cell line development
  • Cell line market trends by source – mammalian and non-mammalian, and influencing factors
  • Market outlook for cell lines across drug discovery, bioproduction, toxicity testing, and tissue engineering
  • CAR-T cell development and manufacturing
  • Growth prospects in the primary cell line and tissue engineering
  • Use cases of 3D cell culture in primary cell lines
  • The growing use of reagents and media, and technical best practice
  • In-source or out-source cell line development
  • Best practice to ensure clonality in new cell lines and legacy cell lines
  • Procs and cons of generation sequencing (NGS) for proving the clonality of legacy production cell lines
  • The use of synthetic biology to help understand success and failure in cell line development
  • CRIPSR in cell line development
  • Comparingculture methods – batch, fedbatch, and perfusion processes
  • Tailoring cell line development programs for your project

Part of

5th Annual BioPharma Development and Production Week »

With demonstrated success year on year, IBC’s BioPharma Development and Production Week in China enjoys unparalleled industry support. Known for generating knowledge, creating business opportunities, and bringing innovative ideas to the table, the BDP Week is now more impactful than ever with 5 high-level conferences, learning seminars, focused trade shows and business matching to boot.

Co located conferences

The BDP Party!

When: Wednesday, 15 May 2019 at 6.30pm
Where: Shanghai City Bistro, Level 1, Shanghai Marriott Parkview Hotel
Cost: CNY 350 / USD 50 net (inclusive of buffet dinner and free flow wine / beer)

  • Registration is not limited to conference participants and we encourage all who are in the BDP industry to attend.
  • Dinner will only proceed when we have reached 100 participants.
  • Payment is only required when the dinner is confirmed.
  • Participants list for the dinner will be made available online once the registration reaches 100 participants.

agenda

8:00 am

Registration Starts & Morning Coffee

9:00 am

Chairperson’s Opening Remarks

OPENING KEYNOTE SESSIONS JOINT PLENARY SESSIONS WITH 9TH ANNUAL BIOMANUFACTURING, 10TH ANNUAL BIOSIMILARS ASIA, 4TH ANNUAL CLINICAL TRIALS, CELL & GENE THERAPY CONFERENCES

9:05 am

Keynote Address: Enabling the Future of Optimised Biologics for Novel Therapeutics and Drugs

9:30 am

Outlook for China’s BDP Market – Investments, Regulations, Innovation and Vision of Chinese Manufacturers

Senior Representative from Fosun Pharma*,

10:40 am

Morning Networking & Refreshment Break

8TH ANNUAL CELL LINE DEVELOPMENT & ENGINEERING ASIA COMMENCES

11:20 am

Chairperson’s Opening Remarks

ASSURANCE AND PROOF OF MONOCLONALITY

11:30 am

Case Study and Application of Plate Imaging Systems for Clonality

George Hutchinson, Head of Global Distribution, Solentim, UK

12:00 pm

  • Pros and cons of using transposase-mediated integration over site-directed or random integration of plasmid DNA
  • Higher titers for stable transfection pools, and higher titers with improved stability for clones by using transposase
  • Assurance of monoclonality in one seeding and imaging step by use of the Verified In-Situ Plate Seeding (VIPS) system

12:30 pm

Networking Lunch

NEW TECHNOLOGIES AND HOST CELL LINES

1:30 pm

  • The critical role of N-Glycans in the pharmacology of biotherapeutics
  • Next generation sample preparation workflows and advanced analytical tools shorten the time to results from days to hours

2:00 pm

Spotlight Presentation in Characterisation, Small-Scale Analysis, Stable Cell Lines, Quality, Titre

James (Jianguo) Yang, Chief Executive Officer, Tayu Huaxia Biotech Medical Group, China

2:30 pm

  • Transforming and accelerating complex manufacturing processes for bio-therapeutic drugs through novel methods
  • Optimising the drug manufacturing process through the fully-automatable Quantum fluorescence polarisation technology platform and novel ChemStress technology
  • Providing early, key insights to promote the chance of identifying high producing, stable cell clones in a reduced time-frame

3:00 pm

Spotlight Technology Presentation

Dr. Ben Borgo, Associate Director, Assays, Reagents, and Software, Berkeley Lights, U.S.

3:30 pm

Afternoon Networking & Refreshment Break

ADVANCES IN GENOME EDITING TECHNOLOGIES – CRISPR & CAR-T

4:00 pm

CRISPR in Cell Line Development: Applications of CRISPR in Rapid Development of Stable Transgene CHO Cell Lines

Dr. Jianwei Zhu, Chair Professor and Dean of School of Pharmacy, Shanghai Jiao Tong University (SJTU); Director of MOE Engineering Research Center of Cell Engineering and Antibody; President and Chief Executive Officer, Jecho Biopharmaceuticals, China

4:30 pm

  • Selecting the cell source
  • Optimising differentiation conditions with small molecules
  • Choosing bioprocess / bioreactors for cell intensification

5:00 pm

  • Introduction of the target disease
  • Promoterless and nuclease free gene editing method
  • GeneRide effect in vivo

5:30 pm

Chairperson’s Summary and End of Conference Day 1

8:30 am

Morning Coffee

8:50 am

Chairperson’s Opening Remarks

ACCELERATING CELL LINE DEVELOPMENT AND CASE STUDIES

9:00 am

  • Application of targeted integration technology
  • Use stable pool for candidate selection
  • Case study of CLD with speed to IND

10:00 am

  • How we can evaluate biochemical and biological activities?
  • How we can manufacture the bispecific antibody in large scale for its clinical trial?
  • Summarized results of current clinical study of ABL001 (NOV1501)

10:30 am

Morning Networking & Refreshment Break

CONTINUOUS MANUFACTURING AND PURIFICATION

12:00 pm

  • Cell line development as a manufacturing process
  • Productivity of cell line and manufacturing cost
  • Glycosylation monitoring

12:30 pm

Networking Lunch

HIGH THROUGHPUT PLATFORMS FOR CELL LINE DEVELOPMENT

1:30 pm

  • Presented emerging trends and technologies for CHO cell line development and engineering
  • Discussed mammalian systems biotechnology for targeted and precise CHO cell line development and engineering
  • Integrated multi-omics profiles with a genome-scale metabolic model of CHO cells

2:30 pm

  • Feasibility Screening of the Beacon technology
  • Points to consider for platform adoption
  • Ongoing efforts to broaden the applicability

3:00 pm

Panel Discussion: Rise of Platform Technologies: Automation and Big Data Integration in CLD

Dr. John E. Gil IV, Director, Head of Cell Line Generation, Shire HGT, U.S

Dr. Dong-Yup Lee, Associate Professor, College of Engineering, Sung Kyun Kwan University (SKKU), South Korea

Dr. Senyon Choe (Teddy), Professor, Biology, University of California San Diego (UCSD), U.S. and President and Director of Joint Center for Biosciences, South Korea

3:30 pm

Afternoon Networking & Refreshment Break

CLOSING PLENARY PANEL JOINT PLENARY SESSIONS WITH 9TH ANNUAL BIOMANUFACTURING, 10TH ANNUAL BIOSIMILARS ASIA, 4TH ANNUAL CLINICAL TRIALS, CELL & GENE THERAPY CONFERENCES

5:00 pm

Chairperson’s Summary and End of Conference

9:00 am

China’s biopharma industry continues to grow rapidly  and hails as a major investment region in the world. With tides of tech innovation, market growth in CRO, CMO and CDMO, a numerous clinical trials projects lined-up, newly discovered therapies to the market and upgrading manufacturing facilities to name a few. This workshop aims to provide a strategic snapshot of the investment landscape for biopharma medicine, and covers practical aspects on how biotech companies can navigate the investment and pricing options for related drugs and treatments to generate better returns.

You will learn:

  • Financing clinical trials operations
  • R&D investment and financing models
  • Manufacturing financing
  • Financial partnership with Chinese pharma and biotech
  • Biosimilars products financing
  • Going Public and Listing insights
  • Deal, debt and equity structuring

1:00 pm

End of Workshop

pricing

Packages Price
2 Day Conference - International Companies, Global HQ Located Outside ChinaUS $1895Early Bird
2 Day Conference - Local China CompaniesUS $977Early Bird
Group Rate of 2 or more delegates - International Companies, Global HQ Located Outside ChinaUS $1495Early Bird
Group of 2 or more delegates - Local China CompaniesUS $752Early Bird
Group Rate of 4 or more delegates - International Companies, Global HQ Located Outside ChinaUS $1295Early Bird
Group of 4 or more delegates - Local China CompaniesUS $676Early Bird
Gala Dinner (For Non Delegates)US $50Early Bird
Extras Price
Pre Conference Workshop - International Companies, Global HQ Located Outside China US $300
Pre Conference Workshop - Local China Companies US $150
Gala Dinner US $50

Early Bird Rate: Register & Pay by 8 March 2019

  • Multiple Bookings Discount pricing is applicable to groups of 2 or more delegates from the same organisation registering for the same event, at the same time.
  • Fee stated is the discounted price PER DELEGATE. Only one discount applies; either the early bird rate OR group rate.
  • All fees stated include luncheons, refreshments and complete set of documentation. It does not include the cost of accommodation and travel.
  • All delegates from Singapore-based companies are required to pay an additional 7% GST (SINGAPORE EVENTS ONLY)

Sponsorship

Partnership and Profile Building Opportunities are Now Available!
Contact us today to find out how you can position your company as a market leader at this event, and to explore the range of branding and marketing opportunities available.

speakers

Senior Representative from Fosun Pharma*

Richard Wang

CEO, Fosun Kite Biotech, China

He Ting

Chief Executive Officer, ImmunoChina, China

Dong Wei

CEO, Edigene, China

Zonghai Li

President and Chief Executive Officer, CARsgen Therapeutics, China

Peter Luo

CEO, Adagene Pharma, China

Ruirong Yuan

President, Chief Medical Officer and Board Director, Adlai Nortye Biopharma, China

Eddy Wu

China Head/Vice-President, Terns Pharmaceutical, China

Jonathan Zhao 4th Annual Bioprocess and Technology 2018

Jonathan Zhao

PhD, Co-founder and Chief Executive Officer, Hangzhou JUST Biotherapeutics, China

Zhou Mingdong

CEO and Chief Scientist, Zensun, China

Zhengyu Yuan

President & Chief Executive Officer, MicuRx Pharmaceuticals Inc., China

George Hutchinson

Head of Global Distribution, Solentim, UK

Thomas Kelly

Scientist, Cell & Developability Sciences, Pharmaceutical Development & Manufacturing Sciences (PDMS), Janssen R&D, U.S.

Dr. John Yan

Applications Scientist, ProZyme, U.S.

James (Jianguo) Yang

Chief Executive Officer, Tayu Huaxia Biotech Medical Group, China

Dr. Carolanne Doherty

Marketing & Sales Manager, Valitacell, Ireland

Dr. Ben Borgo

Associate Director, Assays, Reagents, and Software, Berkeley Lights, U.S.

Dr. Jianwei Zhu

Chair Professor and Dean of School of Pharmacy, Shanghai Jiao Tong University (SJTU); Director of MOE Engineering Research Center of Cell Engineering and Antibody; President and Chief Executive Officer, Jecho Biopharmaceuticals, China

Dr. Steve Oh

Institute Scientist and Director, Stem Cell Bioprocessing, Bioprocessing Technology Institute, A*STAR, Singapore

Jing Liao

Senior Scientist, LogicBio Therapeutics, U.S.

Jerry Yang

Senior Vice President, Process & Product Development, Hangzhou JUST Biotherapeutics Co., Ltd. China

Minmin Qin

Senior Vice President and Head, CMC, Harbour BioMed, China

Weon-Kyoo You

Vice President and Head, R&D, ABL Bio, Inc., South Korea

Dr. Qinghai Zhao

Vice President, Technical Development and Manufacturing, Forty-Seven Inc. USA

Cuiyun Xu

Director, Upstream Process Development, Shanghai Henlius Biotech, Inc., China

Eric Chang

Head of Cell Line Development, JHL Biotech, Taiwan

Dr. Dong-Yup Lee

Associate Professor, College of Engineering, Sung Kyun Kwan University (SKKU), South Korea

Dr. Senyon Choe (Teddy)

Professor, Biology, University of California San Diego (UCSD), U.S. and President and Director of Joint Center for Biosciences, South Korea

Dr. John E. Gil IV

Director, Head of Cell Line Generation, Shire HGT, U.S

Dr. Alvin Luk

Senior Vice President and Chief Medical Officer, Shanghai Henlius Biotech, Inc., China

Chen-Yuan Lin

Ward Director and Attending Physician at the Division of Hematology and Oncology, China Medical University Hospital, Taiwan

Dr Lin Shiwen

Vice President of Downstream Process Development, WuXi Biologics, China

Xiaodi Su

Senior Investment Manager, Lilly Asia Ventures, China

Jieyu Zou

Vice President, Lilly Asia Ventures, China

when & where

14 - 16 May 2019

Shanghai Marriott Hotel Parkview
333 Guang Zhong Road West, Jing’an District
Shanghai, 200072 China
Phone:+86 21 3669 8888
Fax:+86 21 3669 8668

Cartrina Wang 王洁琼 | Senior Sales Manager-EBC
mhrs.shamp.catering.asstmgr1@marriott.com
T: 86 21 3669 8666 | M:13585605981

https://www.marriott.com/hotels/travel/shamp-shanghai-marriott-hotel-parkview/

contact

Still have a question?

Speaking Opportunities
Genevieve Lim
+65-6508 2472
 
Genevieve.Lim@ibcasia.com.sg

Sponsorship Opportunities
Yvonne Leong
+65 6508 2489

Yvonne.Leong@ibcasia.com.sg

Media & Association Partnership Opportunities
Eileen Tan
+65 6508 2462
eileen.tan@ibcasia.com.sg

sponsors

exhibitors

Partners

Conference Partner Conference Partner

STAY UPDATED ON OUR NEWS & EVENTS

IBC Asia is Singapore's leading event organiser. We conceive, develop and promote our own B2B industry conferences and corporate training courses, and offer tailored managed event solutions.

Find out more